ArticleHealth services research2026
Impact of a National Stepped-Care Model of Opioid Use Disorder Treatment on Access to Medication Therapies Among Homeless-Experienced Veterans.
Article in Health services research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo determine whether the Veterans Health Administration's (VHA) Stepped Care for Opioid Use Disorder Train-the-Trainer (SCOUTT) initiative increased medication treatment for opioid use disorder (MOUD) among persons experiencing homelessness (PEH). STUDY SETTING AND
designWe conducted a national retrospective cohort study of MOUD, including buprenorphine, naltrexone, or methadone, in federal fiscal years (FY) 2016-2020. In late FY2018, VHA regional directors nominated facilities to receive SCOUTT implementation support to expand prescribing of MOUD (primarily buprenorphine) in select primary care, pain, and general mental health settings. We used mixed-effects quasi-Poisson regression models with entropy balancing to estimate the Average Treatment Effect on the Treated in the years after SCOUTT was implemented (FY2019-2020), controlling for pre-implementation levels of MOUD. Secondary analyses applied synthetic difference-in-differences (DiD) to estimate changes associated with SCOUTT. DATA SOURCES AND ANALYTIC SAMPLE: We used yearly pooled cross-sectional data from VHA electronic health records, FY2016-2020. The sample included annual cohorts of PEH with an opioid use disorder diagnosis and ≥ 1 primary care visit in the pre-implementation (FY2016-2018, n = 31,354) or post-implementation (FY2019-2020, n = 20,746) periods. PRINCIPAL
findingsFrom FY2016-2020, MOUD receipt increased more in SCOUTT facilities (n = 30, 45.0% to 61.1%) than in non-SCOUTT facilities (n = 811, 41.9% to 49.7%). In post-implementation years, PEH in SCOUTT facilities, compared to non-SCOUTT facilities, were more likely to receive any MOUD (risk difference [RD] = 6.16, 95% CI = 2.33-9.99), including buprenorphine (RD = 7.16, 95% CI = 4.35-9.97). There were no significant differences in methadone (RD = -0.19, 95% CI = -1.03-0.65) or naltrexone (RD = 0.10, 95% CI = -1.85-2.05). Synthetic DiD offered similar results: any MOUD DiD = 7.85, 95% CI = 2.15-13.55; buprenorphine DiD = 9.31, 95% CI = 3.56-15.06.
conclusionsA national initiative to advance a stepped-care model that encourages MOUD initiation outside specialty addiction settings improved access to buprenorphine among PEH. Similar initiatives could help to close treatment gaps in health care settings serving PEH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.